Data and analytics company, GlobalData, has observed substantial gains in market share across the seven major markets (7MM) of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT-2) inhibitors.
Market share
Both drug classes had combined sales that exceeded $8 billion in 2017, which can be attributed to the glycaemic and non-glycaemic benefits they offer — such as CV benefits, weight and/or blood pressure reductions.